Breast Cancer AI Company FathomX Raises SGD$ 2.24 million in Pre-series A Funding
SINGAPORE, Sept. 1, 2022 /PRNewswire/ -- Singapore-based digital health AI company FathomX, a spin-off company from the National University of Singapore (NUS) and National University Health System (NUHS), recently raised a Pre-series A fund of SGD$ 2.24 million in the lead up to Series A funding. Through this funding, the company will be...
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma
XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. XPOVIO® is the first of a new class of SINE medicines to...
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
Addition increases diversity of Board governance and supports further independent expertise DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the appointment of...
The ECO-Friendly Anti-nausea and Vomiting wristband: Emeterm PLUS
VANCOUVER, BC, Sept. 1, 2022 /PRNewswire/ -- WAT Medical is thrilled to introduce its latest innovative technology that would help the millions of people who suffer from nausea and vomiting, the EmeTerm Plus, while also developing an eco-friendly roadmap that would benefit future innovations. The original anti-nausea wristband, EmeTerm, received its FDA clearance in 2018. It has entered the...
AI Startup AESOP Raises $3M to Tackle Medical and Billing Errors
SAN FRANCISCO, Sept. 1, 2022 /PRNewswire/ -- Digital health startup AESOP Technology has raised a $2.95 million series pre-A round to address the growing medical and billing errors problem. The round was led by Taiwania Capital with participation from Colopl Next, 500 Startups, and BE Capital. Originally from Taiwan, AESOP started as a university spin-off from Taipei Medical University (TMU). Professor Yu Chuan...
Broncus (02216.HK) announced interim results
The operating revenue had a year-on-year increase by 12.8% in 2022, and the loss narrowed by 62.8%, gradually forming a closed-loop model of "diagnosis + treatment+ chronic disease management" for major pulmonary diseases HANGZHOU, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, 2022, Broncus (02216.HK), the leader in the field of interventional pulmonology in China, reported its interim...
Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs. This academic and industry relationship will establish independent cell and gene therapy companies to advance the development of...
WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey
CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced the release of its GMP phase I drug substance clinical manufacturing facility, MFG18, in Cranbury, New Jersey. The site's clinical manufacturing operations have an initial capacity of 4,000L and will grow to 6,000L, utilizing...
Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction
Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ -- Frost & Sullivan recently researched the artificial intelligence (AI)-enabled drug safety prediction technology industry and, based on its...
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. held a signing ceremony with Phil. Pharmawealth, Inc. for their cooperation in jointly promoting the registration, promotion, distribution, marketing, and sales of Beijing Minhai's 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide...
